Webinar: MultiTAA-Specific T Cells: A Novel Treatment for Cancer

One of the major limitations of engineered T cell therapies for treating cancer, such as CAR-T and TCR, is their ability to target only a single antigen. Although these therapies can initially provide a significant response, these treatments can eventually lead to tumor resistance through antigen escape mechanisms.

In this webinar, Juan F. Vera presents a novel technique for targeting up to six antigens, providing a more potent and durable anti-tumor response, without the need for genetic modification. The Multi-Antigen Targeted (MultiTAA) cell therapy approach is currently being utilized in clinical trials for treatment of hematological malignancies, displaying high safety and efficacy. During Juan's presentation, you will gain insight into:

• The enhanced patient outcomes achieved by targeting multiple antigens through MultiTAA T cell therapies
• Notable process improvements carried out by Marker Therapeutics resulting in reduced manufacturing time, decreased contamination risks, and significant cost savings
• Applications of MultiTAA in ongoing clinical trials to treat patients with acute myeloid leukemia (AML) and non-Hodgkin lymphoma (NHL)

Speaker:

Juan F. Vera
President & CEO, Marker Therapeutics

For the past 19 years, Juan F. Vera has worked extensively on developing novel T cell therapies for clinical applications and has extensive expertise in performing research in the field of adoptive T cell therapy. Before joining Marker Therapeutics, Juam was an Associate Professor in the Department of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston. He is currently a co-investigator on several clinical trials for T cell therapy in both infectious disease and cancer. Throughout his career, Juan has published more than 30 articles and is a named inventor on 13 published patents.

This presentation was recorded as part of the Virtual Immune Cell Therapy Symposium on September 27, 2023.